Cytek Biosciences Announces $50 Million Stock Repurchase Program
19 Maio 2023 - 10:00AM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced that its Board of Directors has
approved the repurchase of up to an aggregate of $50 million of its
common stock, subject to compliance with applicable law. The
Company’s common stock is listed on The Nasdaq Global Select Market
under the symbol “CTKB”. The repurchase program will continue until
the end of the fiscal year unless extended or shortened by the
Board of Directors.
Any repurchases would be made in the open market
and/or in privately negotiated transactions, and may be made from
time to time or in one or more larger repurchases. The program will
be conducted in compliance with the Securities and Exchange
Commission's Rule 10b-18 and applicable legal requirements. The
amount and timing of any repurchases made under the repurchase
program will depend on a variety of factors, including available
liquidity, cash flow and market conditions.
The program does not obligate the Company to
acquire any particular amount of our common stock and the program
may be modified or suspended at any time at the Company's
discretion.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Aurora and Northern Lights™ systems; its cell sorter, the
Aurora CS; the flow cytometer and imaging products under the Amnis®
and Guava® brands; and reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and
distribution channels across the globe. More information about the
company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system
and certain reagents for use therewith, which are available for
clinical use in countries where the regulatory approval has been
obtained from the local regulatory authorities, including China and
the European Union, Cytek’s products are for research use only and
not for use in diagnostic procedures. Please contact your local
sales representatives for the status of local regulatory
approval.
Cytek, Full Spectrum Profiling, FSP, Northern
Lights, cFluor, Amnis and Guava are trademarks of Cytek
Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and corporate Twitter account as channels of distribution
of information about its company, products, planned financial and
other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Cytek may use these channels to comply
with its disclosure obligations under Regulation FD. Therefore,
investors should monitor Cytek’s website, LinkedIn page, and
Twitter account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 as contained in Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, which are subject to the “safe harbor”
created by those sections. All statements other than statements of
historical facts, including statements regarding our future
activity, if any, under the share repurchase program, including the
timing of any such repurchases, are forward-looking statements. In
some cases, you can identify forward-looking statements because
they contain words such as “anticipate,” “believe,” “contemplate,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or
expressions. These statements are based on management’s current
expectations, forecasts, beliefs, assumptions and information
currently available to management. These statements also deal with
future events and involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. You
should refer to the section entitled “Risk Factors” set forth in
Cytek Biosciences’ Annual Report on Form 10-Q filed on May 9, 2023
with the SEC, and other filings Cytek Biosciences makes with the
SEC from time to time for a discussion of important factors that
may cause actual results to differ materially from those expressed
or implied by Cytek Biosciences’ forward-looking statements.
Although Cytek Biosciences believes that the expectations reflected
in the forward-looking statements are reasonable, it cannot provide
any assurance that these expectations will prove to be correct nor
can it guarantee that the events and circumstances reflected in the
forward-looking statements will occur. The forward-looking
statements in this press release are based on information available
to Cytek Biosciences as of the date hereof, and Cytek Biosciences
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Cytek Biosciences’ views
as of any date subsequent to the date of this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024